摘要
目的探讨联合使用经导管内肝动脉化疗栓塞(Trans-catheter hepatic arterial chemoembolization,TACE)与经皮乙醇碘化油注射(Percutaneous Ethanol-Lipiodol Injection,PELI)治疗不可切除肝细胞癌的临床疗效和安全性。方法122例(男109例,女13例,平均年龄52岁)不可切除肝细胞癌患者纳入此项非随机对照研究。54例接受TACE联合PELI(实验组)治疗,余下的68例接受单纯TACE(对照组)治疗,并随访12个月。分析两组的临床治疗反应、生存率、无进展生存期及毒副作用的差异性。结果实验组Ⅰ、Ⅱ和Ⅲ期治疗的临床反应明显高于对照组(84.6%、78.6%、59.3%与66.7%、45.8%、31.0%),患者累计生存率和无进展生存期均较对照组延长(P<0.05)。亚组分析中,II期患者在联合治疗中明显获益,其累计生存率和无进展生存期较对照组明显延长(P=0.025或P=0.001)。结论TACE联合PELI可以提高不可切除肝癌患者的临床治疗反应和远期疗效,是一种安全有效的治疗方法。
Objective To analyze the efficacy and safety of Percutaneous Ethanol-Lipiodol Injection （PELI） in patients with unresectable hepatocellular carcinoma in the combination of Trans-catheter hepatic arterial chemoembolization （TACE）. Mmethods 122 patients with unresectable hepatocellular carcinoma were enrolled in the non-randomized clinical trial. 54 received a combination treatment of TACEand PELI （the experiment group）, while the remaining 68 were treated with only TACE （the control group）. Patients were followed up for 12 months, with safety and clinical response e- valuated by National Cancer Instituters Common Toxicity Criteria and response evaluation criteria in solid tumor （RE- CIST）, respectively. PFS and survival rates were also analyzed by Kaplan-Meier method. Results In the study, the experiment group had better clinical response than control group（84.6%, 78. 6%, 59.3% VS 66. 7%, 45.8%, 31.0% ）, cumulative survival rate and PFS also （P〈0. 05）. In Subgroup analysis, stag eII gained more benefit from this conjoined treatment, especially in cumulative survival rate and PFS（P=0. 025 ,P=0. 001）. Conclusions Our results show that the combination of TACE and PELI is safe and effective for unresectable hepatocellular carcinoma.
出处
《西部医学》
2010年第4期667-670,共4页
Medical Journal of West China
关键词
经导管内肝动脉化疗栓塞
经皮的无水乙醇碘化油注射
不可切除肝癌
Trans-catheter hepatic arterial chemoembolization（TACE）
Percutaneous Ethanol-Lipiodol Injection （PELI）
Unresectable Hepatocellular carcinoma
